Startup profile · funding coverage
Ciitizen funding, valuation and investors
Patient-consented medical records platform for cancer and chronic care.
Keep track of Ciitizen
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$17M · January 2019
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$17M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Ciitizen helped patients exercise HIPAA rights to collect and share medical records for cancer and chronic care — aggregating records for trials and research. a16z Bio led seed and a $17M Series A in 2019. Invitae acquired Ciitizen in September 2021 for approximately $325M in cash and stock.
Why Ciitizen is interesting
Ciitizen used HIPAA access rights to aggregate records for trials and research — a16z Bio led seed and Series A before Invitae's $325M acquisition.
Product & use cases
Patient-consented medical records platform using HIPAA access rights to aggregate records for research and care coordination.
- Cancer patient record aggregation for trials
- Chronic care record portability
- Research-grade patient data consented sharing
Key facts
- Acquired by Invitae (Sep 2021): ~$325M cash and stock (PR Newswire, MedCity News)
- Series A (Jan 2019): $17M led by a16z Bio; Section 32, Verily participated (TechCrunch)
- Source: https://www.prnewswire.com/news-releases/invitae-to-acquire-ciitizen-to-strengthen-its-patient-consented-health-data-platform-to-improve-personal-outcomes-and-global-research-301369974.html
Funding history (newest first)
Investors in our directory
Funds linked from Ciitizen's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Ciitizen differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.
Ciitizen operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.
-
Apple Health Records adjacent
Consumer health record aggregation; Ciitizen cancer/chronic focus.
-
Invitae direct
Acquirer; integrated Ciitizen into patient data platform.
Notable stories
- Acquired by Invitae (Sep 2021): ~$325M cash and stock (PR Newswire, MedCity News)
- Series A (Jan 2019): $17M led by a16z Bio; Section 32, Verily participated (TechCrunch)
Industries
Related funding articles
Venture Capital Tracker pieces that cover Ciitizen's financing or category context.
FAQs about Ciitizen
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.